Advancing Monoclonal Antibodies Development with iLite® CDC Bioassays
Newsletter

Advancing Monoclonal Antibodies Development with iLite® CDC Bioassays

This comprehensive white paper delves into the intricacies of assessing antibody-mediated complement‐dependent cytotoxicity (CDC) activity, showcasing the iLite CDC platform's exceptional accuracy, efficiency, and adaptability in developing transformative therapeutic monoclonal antibodies.

  • Gain insights into the high linearity between antibody concentrations and Svar luciferase quantification, which is crucial for precise CDC activity assessment.
  • Learn about the robustness of the iLite CDC bioassay, designed to accommodate a wide range of serum concentrations without compromising on performance.
  • Explore how our cell engineering expertise enables the customization of the bioassay platform to suit any surface antigen, providing unparalleled support and flexibility.

The iLite CDC Bioassay platform offers a comprehensive solution for evaluating complement-dependent cytotoxicity. Whether you're involved in novel therapeutic monoclonal antibody development seeking to enhance CDC activity or looking to inhibit CDC activity, our whitepaper is an essential resource for empowering your projects in the diverse landscape of disease treatment.

Download our white paper today and take the first step towards harnessing the full potential of antibody-mediated CDC in your research endeavors.

Fill in the form to access the free white paper